| Title |
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
|
|---|---|
| Published in |
Psychopharmacology, April 2018
|
| DOI | 10.1007/s00213-018-4885-9 |
| Pubmed ID | |
| Authors |
Douglas L. Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M. Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C. D’Souza, Mohini Ranganathan |
| Abstract |
Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial. This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly. There was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug × time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group. At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects. https://clinicaltrials.gov/ct2/show/NCT00588731. |
X Demographics
The data shown below were collected from the profiles of 34 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 24% |
| Australia | 3 | 9% |
| Japan | 2 | 6% |
| Sweden | 2 | 6% |
| Denmark | 2 | 6% |
| Canada | 2 | 6% |
| Brazil | 1 | 3% |
| Iceland | 1 | 3% |
| Germany | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 12 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 68% |
| Scientists | 7 | 21% |
| Science communicators (journalists, bloggers, editors) | 2 | 6% |
| Practitioners (doctors, other healthcare professionals) | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 394 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 394 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 56 | 14% |
| Student > Master | 44 | 11% |
| Researcher | 43 | 11% |
| Student > Ph. D. Student | 33 | 8% |
| Other | 31 | 8% |
| Other | 50 | 13% |
| Unknown | 137 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 61 | 15% |
| Neuroscience | 42 | 11% |
| Psychology | 36 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 27 | 7% |
| Biochemistry, Genetics and Molecular Biology | 18 | 5% |
| Other | 54 | 14% |
| Unknown | 156 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 200. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2024.
All research outputs
#197,318
of 25,388,177 outputs
Outputs from Psychopharmacology
#54
of 5,318 outputs
Outputs of similar age
#4,559
of 343,530 outputs
Outputs of similar age from Psychopharmacology
#1
of 43 outputs
Altmetric has tracked 25,388,177 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,318 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,530 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.